|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
121,380,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood-based tests, data sets and analytics. Co. is engaged in the clinical liquid biopsy market with its Guardant360 and GuardantOMNI tests. Co.'s Guardant360 test is a molecular diagnostic test measuring a number of cancer-related genes and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. In addition, Co. is developing tests from its LUNAR-1 program for minimal residual disease and recurrence detection in cancer survivors, and its LUNAR-2 program for early detection of cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
2,187 |
98,220 |
Total Buy Value |
$0 |
$0 |
$38,963 |
$2,585,297 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
1 |
4 |
Total Shares Sold |
0 |
100 |
6,100 |
20,716 |
Total Sell Value |
$0 |
$2,787 |
$160,280 |
$706,446 |
Total People Sold |
0 |
1 |
2 |
2 |
Total Sell Transactions |
0 |
1 |
4 |
9 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Talasaz Amirali |
Chairman, President and COO |
|
2020-10-27 |
4 |
AS |
$105.35 |
$8,129,541 |
I/I |
(75,851) |
620,800 |
|
- |
|
Clark Ian T |
Director |
|
2020-10-26 |
4 |
AS |
$104.03 |
$55,968 |
D/D |
(538) |
4,643 |
|
- |
|
Clark Ian T |
Director |
|
2020-10-26 |
4 |
OE |
$4.18 |
$2,249 |
D/D |
538 |
5,181 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-10-26 |
4 |
AS |
$105.02 |
$484,472 |
I/I |
(4,613) |
696,651 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-10-23 |
4 |
AS |
$105.15 |
$1,381,315 |
I/I |
(13,136) |
701,264 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-10-16 |
4 |
AS |
$101.81 |
$2,397,132 |
I/I |
(23,400) |
714,400 |
|
- |
|
Kaul Samir |
Director |
|
2020-10-16 |
4 |
AS |
$101.29 |
$1,018,793 |
I/I |
(10,000) |
51,943 |
|
- |
|
Meresman Stanley J |
Director |
|
2020-10-12 |
4 |
AS |
$109.37 |
$546,850 |
D/D |
(5,000) |
4,059 |
|
- |
|
Meresman Stanley J |
Director |
|
2020-10-12 |
4 |
OE |
$5.94 |
$29,700 |
D/D |
5,000 |
9,059 |
|
- |
|
Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
|
2020-10-09 |
4 |
S |
$101.08 |
$707,574,000 |
I/I |
(7,000,000) |
7,037,960 |
|
- |
|
Clark Ian T |
Director |
|
2020-10-05 |
4 |
AS |
$108.50 |
$291,865 |
D/D |
(2,690) |
4,643 |
|
- |
|
Clark Ian T |
Director |
|
2020-10-05 |
4 |
OE |
$4.18 |
$11,244 |
D/D |
2,690 |
7,333 |
|
- |
|
Clark Ian T |
Director |
|
2020-09-25 |
4 |
AS |
$106.24 |
$57,157 |
D/D |
(538) |
4,643 |
|
- |
|
Clark Ian T |
Director |
|
2020-09-25 |
4 |
OE |
$4.18 |
$2,249 |
D/D |
538 |
5,181 |
|
- |
|
Talasaz Amirali |
Chairman, President and COO |
|
2020-09-25 |
4 |
AS |
$110.44 |
$8,303,375 |
D/D |
(75,000) |
2,539,532 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-18 |
4 |
AS |
$100.57 |
$6,679,062 |
D/D |
(65,422) |
2,819,530 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-18 |
4 |
OE |
$4.18 |
$56,973 |
D/D |
13,630 |
2,884,952 |
|
- |
|
Kaul Samir |
Director |
|
2020-09-17 |
4 |
AS |
$99.23 |
$1,008,264 |
I/I |
(10,000) |
61,943 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-17 |
4 |
AS |
$99.16 |
$20,722,636 |
D/D |
(206,021) |
2,871,322 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-17 |
4 |
OE |
$4.18 |
$179,410 |
D/D |
42,921 |
3,077,343 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-16 |
4 |
AS |
$103.05 |
$22,707,933 |
D/D |
(218,509) |
3,034,422 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-16 |
4 |
OE |
$4.18 |
$190,286 |
D/D |
45,523 |
3,252,931 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-15 |
4 |
AS |
$102.21 |
$11,359,063 |
D/D |
(110,048) |
3,207,408 |
|
- |
|
Eltoukhy Helmy |
Chief Executive Officer |
|
2020-09-15 |
4 |
OE |
$4.18 |
$95,831 |
D/D |
22,926 |
3,317,456 |
|
- |
|
Saia John G. |
See Remarks |
|
2020-09-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,491 |
15,903 |
|
- |
|
681 Records found
|
|
Page 15 of 28 |
|
|